Cargando…
Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX
Protein specific aptamers are highly applicable affinity ligands in different fields of research and clinical applications. They have been developed against various targets, in particular, bio-macromolecules such as proteins. Among human proteins, the coagulation factors are the most attractive targ...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603883/ https://www.ncbi.nlm.nih.gov/pubmed/28979328 |
_version_ | 1783264786505531392 |
---|---|
author | Vahidi, Hossein Nafissi-Varcheh, Nastaran Kazemi, Bahram Aboofazeli, Reza Shahhosseini, Soraya Tabarzad, Maryam |
author_facet | Vahidi, Hossein Nafissi-Varcheh, Nastaran Kazemi, Bahram Aboofazeli, Reza Shahhosseini, Soraya Tabarzad, Maryam |
author_sort | Vahidi, Hossein |
collection | PubMed |
description | Protein specific aptamers are highly applicable affinity ligands in different fields of research and clinical applications. They have been developed against various targets, in particular, bio-macromolecules such as proteins. Among human proteins, the coagulation factors are the most attractive targets for aptamer selection and their specific aptamers have valuable characteristics in therapeutic and analytical applications. In this study, a plasma derived coagulation factor VIII was considered as the protein target for DNA aptamer selection using size exclusion chromatography-SELEX. Potential aptameric oligonucleotides with high affinity and specificity were achieved during eight rounds of selection. Binding affinity constant of selected aptamer and aptameric enriched pool were in nanomolar range that was comparable to monoclonal antibodies. Further improvement studies can result in aptamers that are more promising as an industrial affinity ligand for the purification of anti-hemophilia factor from plasma source. |
format | Online Article Text |
id | pubmed-5603883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Shaheed Beheshti University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-56038832017-10-04 Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX Vahidi, Hossein Nafissi-Varcheh, Nastaran Kazemi, Bahram Aboofazeli, Reza Shahhosseini, Soraya Tabarzad, Maryam Iran J Pharm Res Original Article Protein specific aptamers are highly applicable affinity ligands in different fields of research and clinical applications. They have been developed against various targets, in particular, bio-macromolecules such as proteins. Among human proteins, the coagulation factors are the most attractive targets for aptamer selection and their specific aptamers have valuable characteristics in therapeutic and analytical applications. In this study, a plasma derived coagulation factor VIII was considered as the protein target for DNA aptamer selection using size exclusion chromatography-SELEX. Potential aptameric oligonucleotides with high affinity and specificity were achieved during eight rounds of selection. Binding affinity constant of selected aptamer and aptameric enriched pool were in nanomolar range that was comparable to monoclonal antibodies. Further improvement studies can result in aptamers that are more promising as an industrial affinity ligand for the purification of anti-hemophilia factor from plasma source. Shaheed Beheshti University of Medical Sciences 2017 /pmc/articles/PMC5603883/ /pubmed/28979328 Text en © 2017 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Vahidi, Hossein Nafissi-Varcheh, Nastaran Kazemi, Bahram Aboofazeli, Reza Shahhosseini, Soraya Tabarzad, Maryam Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX |
title | Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX |
title_full | Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX |
title_fullStr | Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX |
title_full_unstemmed | Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX |
title_short | Challenges to Design and Develop of DNA Aptamers for Protein Targets. II. Development of the Aptameric Affinity Ligands Specific to Human Plasma Coagulation Factor VIII Using SEC-SELEX |
title_sort | challenges to design and develop of dna aptamers for protein targets. ii. development of the aptameric affinity ligands specific to human plasma coagulation factor viii using sec-selex |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603883/ https://www.ncbi.nlm.nih.gov/pubmed/28979328 |
work_keys_str_mv | AT vahidihossein challengestodesignanddevelopofdnaaptamersforproteintargetsiidevelopmentoftheaptamericaffinityligandsspecifictohumanplasmacoagulationfactorviiiusingsecselex AT nafissivarchehnastaran challengestodesignanddevelopofdnaaptamersforproteintargetsiidevelopmentoftheaptamericaffinityligandsspecifictohumanplasmacoagulationfactorviiiusingsecselex AT kazemibahram challengestodesignanddevelopofdnaaptamersforproteintargetsiidevelopmentoftheaptamericaffinityligandsspecifictohumanplasmacoagulationfactorviiiusingsecselex AT aboofazelireza challengestodesignanddevelopofdnaaptamersforproteintargetsiidevelopmentoftheaptamericaffinityligandsspecifictohumanplasmacoagulationfactorviiiusingsecselex AT shahhosseinisoraya challengestodesignanddevelopofdnaaptamersforproteintargetsiidevelopmentoftheaptamericaffinityligandsspecifictohumanplasmacoagulationfactorviiiusingsecselex AT tabarzadmaryam challengestodesignanddevelopofdnaaptamersforproteintargetsiidevelopmentoftheaptamericaffinityligandsspecifictohumanplasmacoagulationfactorviiiusingsecselex |